<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">8980405</article-id><article-id pub-id-type="pmc">2074814</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Weekly doxorubicin and continuous infusional 5-fluorouracil for advanced breast cancer.</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Gabra</surname><given-names>H.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Cameron</surname><given-names>D. A.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Lee</surname><given-names>L. E.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Mackay</surname><given-names>J.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Leonard</surname><given-names>R. C.</given-names></name></contrib></contrib-group><aff>ICRF Medical Oncology Unit, Western General Hospital, Edinburgh, UK.</aff><pub-date pub-type="ppub"><month>12</month><year>1996</year></pub-date><volume>74</volume><issue>12</issue><fpage>2008</fpage><lpage>2012</lpage><abstract><p>Drug scheduling alterations can improve the therapeutic index of both 5-fluorouracil and anthracyclines. We investigated a regimen of weekly doxorubicin and continuous infusional 5-fluorouracil (AcF) in loco-regionally recurrent and metastatic breast cancer. The aims of this phase II study were to use low-dose weekly anthracyclines in a patient group where liver metastases are a frequent problem, to optimise scheduling of 5-fluorouracil using continuous infusion and to conserve alkylating agent use for late intensification in responding patients. Fifty-six patients received 5-fluorouracil 200 mg m-2 day-1 and doxorubicin 20-30 mg m-2 week-1 for at least 6 weeks. Sixty-two percent were chemonaive. Patients were evaluated for dose intensity, response, toxicity and survival. Of the assessable patients, 76% achieved UICC response criteria (20% complete response, 56% partial response). WHO grade 3+ toxicities were: alopecia, 98%; mucositis, 62%; neutropenia, 22%; and grade 3 palmar-plantar syndrome, 24%. Median survival was 13 months, with visceral metastasis conferring a significantly worse outcome (P = 0.03). Grade 3+ mucositis was more frequent with planned doxorubicin dose intensity &#x0003e; or = 25 mg m-2 week-1 (P = 0.04). AcF is highly active in breast cancer with acceptable toxicities and can be used before alkylating agent-based high-dose therapy.</p></abstract></article-meta></front><body><supplementary-material content-type="scanned-pages"><graphic xlink:href="brjcancer00028-0158.tif" xlink:title="scanned-page" xlink:role="2008" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00028-0159.tif" xlink:title="scanned-page" xlink:role="2009" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00028-0160.tif" xlink:title="scanned-page" xlink:role="2010" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00028-0161.tif" xlink:title="scanned-page" xlink:role="2011" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00028-0162.tif" xlink:title="scanned-page" xlink:role="2012" mimetype="image" mime-subtype="tiff"/></supplementary-material></body></article>

